정규장
로그인 회원가입
WAT
Waters Corp
7월 27일 12:35 PM ET (한국 7/28 01:35)
$374.68
-7.73 ▼ -2.02%

워터즈(WAT) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$36.8B
미드캡
P/E
47.7
적정 수준
배당수익률
없음
52주 위치
72%
저점 +36% · 고점 -10%
애널리스트
매수
C+
Fundamental health
vs. Diagnostics & Research
수익성
Top 59%
성장
Top 61%
밸류에이션
Top 32%
재무 안정
Top 47%
Index S&P 500P/E 47.7EPS (ttm) 7.86Insider Own 0.1%Shs Outstand 98.2MPerf Week 1.54%
Market Cap 36.79BForward P/E 22.77EPS next Y 13.3%Insider Trans 1.55%Shs Float 98.1MPerf Month 1.49%
Enterprise Value 41.90BPEG 1.95EPS next Q 3.01Inst Own 98.51%Short Float 3.77%Perf Quarter 20.4%
Income 0.45BP/S 9.76EPS this Y 10.61%Inst Trans 66.19%Short Ratio 3.61Perf Half Y -6.43%
Sales 3.77BP/B 2.41EPS next 5Y 11.68%ROA 3.09%Short Interest 3.70MPerf YTD -1.36%
Book/sh 155.78P/C 79.63EPS past 3/5Y -2.83% 5.19%ROE 5.21%52W High -9.53% ($414.15)Perf Year 25.53%
Cash/sh 4.71P/FCF 152.85Sales past 3/5Y 2.12% 6%ROIC 2.2%52W Low 36.22% ($275.05)Perf 3Y 30.56%
Dividend Est. -EV/EBITDA 37.83EPS Y/Y TTM -28.79%Gross Margin 50.21%Volatility(W/M) 4.32% 3.01%Perf 5Y -2.6%
Dividend TTM -EV/Sales 11.11Sales Y/Y TTM 26.39%Oper. Margin 19.72%ATR (14) 12.24Perf 10Y 150.79%
Dividend Ex-Date -Quick Ratio 1.13EPS Q/Q -143.12%Profit Margin 11.91%RSI (14) 53.23Recom 2
Dividend Gr. 3/5Y -Current Ratio 1.79Sales Q/Q 91.48%SMA20 0.24% ($373.78)Beta 1.18Target Price $416.18
Payout -Debt/Eq 0.36Earnings 2026/8/4SMA50 3.1% ($363.41)Rel Volume 0.8Prev Close $382.41
Employees 7900LT Debt/Eq 0.34EPS/Sales Surpr. 17.04% 5.3%SMA200 6.1% ($353.14)Avg Volume(3M) 1.03MPrice $374.68
IPO 1995/11/17Option/Short Yes/YesTrades 15123Volume 819,018Change -2.02%
Quarterly earnings trend SEC filings · USD
25.3
25.3
25.6
25.6
25.9
25.9
25.12
26.4
Revenue Net income 최근 분기: 매출 $1.3B (YoY +91%) · 순이익 $-72M (YoY -160%)

📊 Waters Corp (WAT) Investment Analysis

What kind of company is Waters Corp?

워터즈(WAT) 성장주
Healthcare · Diagnostics & Research
Top 399 by Market Cap — Large-Cap

🧪 A global analytical science company that supplies analytical instrumentation such as liquid chromatography and mass spectrometry, along with precision chemical consumables. Founded in 1958 and headquartered in Massachusetts, USA, it is regarded as a high-quality analytical instrumentation stock holding a global leading position in the high-performance liquid chromatography field.

Learn more about Waters Corp →
Market Cap
$36.8B
Approx. KRW 50.4 trillion
⚖️ 13% of Samsung Electronics
Market Cap Rank399
Employees7,900people
IPO1995/11/17
Current Price$374.68 ≈ 513,312원
📌 S&P 500 · NYSE · USA

Key Events

⏰ Upcoming events
🔔 Earnings release D-8
예상 EPS $3.01
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 5일 (화) · 장 시작 전 EPS +17.0% 매출 +5.3%
🔔 Earnings release 2026년 2월 9일 (월) · 장 시작 전 EPS +0.5% 매출 +0.4%

Is it profitable?

Financial health solid
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
19.7%
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research 대형주 Median 18.9% · Top 41%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
11.9%
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research 대형주 Median 11.9% · Around average
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
50.2%
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research 대형주 Median 50.2% · Around average
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
5.2%
✓ 평균
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 11.9% · Bottom 29%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
3.1%
✓ 평균
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 5.1% · Bottom 33%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
2.2%
✓ 부진
My positionBottom 25%
Low range Average High range
Healthcare 대형주 Median 7.4% · Bottom 25%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.36
✓ Healthy debt
My positionMid-range
Low range Average High range
Diagnostics & Research Median 0.38
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.79
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 2.23
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.13
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 2.15
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$416.18
현재가 대비 +11.1%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
22.77배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
1.95
다소 비쌈
💡 PEG 1.5~2 — 성장 대비 다소 비쌈
내년 EPS 예상 성장률
+13.3%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+11.7%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Slight tendency to beat estimates
1
예상 상회
1
예상 부합
0
예상 하회
50%
상회 비율
+8.7%
평균 서프라이즈
2026.05.05
상회
실적 $2.70 · 예상 $2.31 +17.0%
2026.02.09
부합
실적 $4.53 · 예상 $4.51 +0.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Top-Line Growth Only Revenue is growing while EPS is flat — a possible sign of weakening profitability
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+10.6%
평균
My positionMid-range
Low range Average High range
성장주 대형주 Median 15.4% · Bottom 26%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+13.3%
양호
My positionMid-range
Low range Average High range
성장주 대형주 Median 13.1% · Top 49%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+11.7%
평균
My positionMid-range
Low range Average High range
성장주 대형주 Median 14.9% · Bottom 27%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-2.8%
부진
My positionBottom 25%
Low range Average High range
성장주 대형주 Median 9.2% · Bottom 24%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+5.2%
부진
My positionBottom 25%
Low range Average High range
성장주 대형주 Median 13.8% · Bottom 21%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+6.0%
부진
My positionBottom 25%
Low range Average High range
성장주 대형주 Median 10.3% · Bottom 23%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+91.5%
우수
My positionTop 5%
Low range Average High range
성장주 대형주 Median 11.2% · Top tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -71%p below the market
WAT -2.6% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-70.6%p
Significantly behind the market
vs Health Care (XLV)
-26.3%p
behind the sector average
1-year basis
vs S&P 500
+9.1%p
slightly ahead of the market
vs Health Care (XLV)
+5.8%p
slightly ahead of the sector average
Rank among peers
5-year return Upper-Mid (45%) Based on 15 peers
1-year return Upper-Mid (35%) Based on 15 peers
Current position within 52-week range
Low (-36.2%p) High (-9.5%p)
Current price is 36.2% above the 52-week low and 9.5% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-26.3%
Annualized volatility
43.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡
Current diagnosis · 2026-07-24
Squeeze — volatility contraction, breakout imminent

Band width narrowed to 5.8%. Big move may be near. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-24
Neutral zone — weak trend

MACD 2.770 · Signal 3.448 · Hist -0.677. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-24
Bullish zone

RSI 53.2 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 65.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average
Cheap on Vs. Earnings·Vs. Assets, Pricey on Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Cheap
🧾 Vs. Sales Pricey
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
47.70x
✓ Fair
My positionMid-range
Low range Average High range
Diagnostics & Research median 35.22x · Around the industry average
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
22.77x
✓ Cheap
My positionMid-range
Low range Average High range
Diagnostics & Research median 22.77x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
2.41x
✓ Cheap
My positionMid-range
Low range Average High range
Diagnostics & Research median 3.37x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
9.76x
✓ Pricey
My positionBottom 25%
Low range Average High range
Diagnostics & Research 대형주 median 5.41x · Bottom 20% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
37.83x
✓ Pricey
My positionBottom 25%
Low range Average High range
Diagnostics & Research median 22.23x · Bottom 25% — expensive within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
152.85x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Diagnostics & Research median 29.34x · Bottom 5% — expensive within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$416.18 vs. current price +11.1%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership flow is positive
Insider modest net buying +1.6% · Institutional net buying +66.2% · Short interest light 3.8% · Short interest up +1.1pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
+1.6%
Insiders net buying
🏦 Institutions (funds & investors)
+66.2%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 98.5%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 0.1%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 1.4%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
3.8%
Low — limited short-side pressure
Healthcare 대형주 Median 3.6%
Past 90 days 📈 +1.1%p increase
Short interest days to cover
3.6 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 98.2M주
Float (tradable shares) 98.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding WAT

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
WAT This Stock
$36.8B47.7 2.4 5.21% - -2.0%
LLY
$1.13T43.0 36.2 107.64% 0.58% +0.9%
JNJ
$634.1B30.5 7.5 25.74% 2.04% +1.6%
ABBV
$458.2B127.9 - 15221.82% 2.65% +0.9%
UNH
$382.1B27.1 3.9 12.49% 2.15% -0.7%
MRK
$323.7B36.9 7.1 18.97% 2.49% +0.5%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 워터즈(WAT)?

워터즈(WAT) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of WAT?

The market cap of WAT is approximately $36.8B, ranking 399 within its sector.

What is the P/E ratio of WAT?

WAT has a P/E ratio of approximately 47.7x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for WAT?

WAT has recorded a 52-week high of $414.15 and a low of $275.05.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.